Analyst Research Report Snapshot

Title:

Genmab A/S

Price:

$175.00

Provider:

MarketLine (a Datamonitor Company)

Date:

08 Apr 2014

Pages:

43

Type:

AcrobatPDF

Companies referenced:

GEN.CO

Available for Immediate Download
Summary:

Genmab A/S - Strategy and SWOT Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360° view of the company. Features: - Detailed information on Genmab A/S required for business and competitor intelligence needs - A study of the major internal and external factors affecting Genmab A/S in the form of a SWOT analysis - An in-depth view of the business model of Genmab A/S including a breakdown and examination of key business segments - Intelligence on Genmab A/S’s mergers and acquisitions (M&A), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors - News about Genmab A/S, such as business expansion, restructuring, and contract wins - Large number of easy-to-grasp charts and graphs that present important data and key trends Highlights: Genmab (or 'the company') is a biotechnology company engaged in the discovery and development of human antibodies for the treatment of life-threatening and debilitating diseases. The company's therapeutic emphasis is in the areas of cancer, infectious diseases, rheumatoid arthritis and other inflammatory conditions. It is headquartered in Copenhagen, Denmark and employed 179 people as of December 31, 2012. The company recorded revenues of DKK484.6 million (approximately $83.7 million) during the financial year ended December 2012 (FY2012), an increase of 38.1% over FY2011. The operating loss of the company was DKK116.7 million (approximately $20.2 million) in FY2012, as compared to an operating loss of DKK249.4 million (approximately $43.1 million). The net loss was DKK487.1 million (approximately $84.1 million) in FY2012, as compared to a net loss of DKK596.4 million (approximately $103 million) in FY2011. Reasons to Purchase: - Gain understanding of Genmab A/S and the factors that influence its strategies - Track strategic initiatives of the company and latest corporate news and actions - Assess Genmab A/S as a prospective partner, vendor or supplier - Support sales activities by understanding your customers' businesses better - Stay up to date on Genmab A/S’s business structure, strategy and prospects

Why buy analyst research?

  • Institutional quality research
  • Available for Immediate Download
  • Detailed company or industry insight
  • Print or save
  • 24 hour customer support
Return to previous page without adding this item to your cart.
Email Customer Support.

About Analyst Research

Analyst research reports are available for immediate download after purchase. You will have unlimited access to the report for 24 hours after purchase, to download, print or save it as many times as you wish. Analyst Research provided by Reuters does not constitute investment advice, and is not endorsed by Reuters Research. This information is protected by copyright and intellectual property laws. More information on Analyst Research.